Major Depressive Disorder Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview: 

The major depressive disorder market reached a value of USD 6.0 Million across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 7.5 Million by 2036, exhibiting a growth rate (CAGR) of 2.06% during 2026-2036.

The major depressive disorder market has been comprehensively analyzed in IMARC's new report titled "Major Depressive Disorder Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Major depressive disorder, also referred to as clinical depression, is a mental condition that causes alterations in brain function, including the disrupted activity of specific neural circuits in the brain. The disease is characterized by at least two weeks of pervasive low mood, loss of interest or pleasure in normally enjoyable activities, and lack of self-esteem. The common symptoms of this condition include inappropriate guilt or regret, feelings of worthlessness, helplessness, poor concentration, reduced sex drive, withdrawal from social situations and activities, irritability, suicidal thoughts, etc. Additionally, individuals suffering from major depressive disorder may experience insomnia, hypersomnia, oversleeping, fatigue, headaches, or digestive problems. Diagnosing this ailment is based on the patient's symptoms, biographical history, and mental status examination. The healthcare provider also performs cognitive tests and brain imaging studies to help distinguish depression from other mental disorders. Various assessment tools, such as the Hamilton Rating Scale for Depression and the Beck Depression Inventory, are utilized to determine the severity of symptoms and confirm a diagnosis.

The rising incidences of several associated risk factors, including stressful life events, medical conditions like chronic illness, psychological factors such as personality traits, etc., are primarily driving the major depressive disorder market. In addition to this, the increasing cases of imbalances in brain chemistry, specifically in the levels of certain neurotransmitters, are also propelling the market growth. Furthermore, the inflating adoption of effective medications, including antidepressants and anxiolytics, to improve mood and reduce symptoms of depression is acting as another significant growth-inducing factor. Apart from this, the escalating application of transcranial magnetic stimulation, a noninvasive treatment procedure that utilizes magnetic fields to stimulate brain nerve cells and alleviate disease indications, is further creating a positive outlook for the market. Moreover, the widespread demand for behavioral interventions, such as interpersonal and cognitive-behavioral therapies, to prevent new-onset depression and change unhealthy thoughts, emotions, and behaviors is also augmenting the market growth. Additionally, the emerging popularity of low-dose psychedelic drugs that boost the activity of glutamate in the brain and improve the patient's mood is expected to drive the major depressive disorder market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the major depressive disorder market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for major depressive disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the major depressive disorder market in any manner.

Recent Developments:

• In December 2025, Biohaven Ltd. announced results from a Phase 2 proof-of-concept clinical study evaluating BHV-7000 for the treatment of major depressive disorder (MDD), providing early clinical insights into its potential efficacy and safety profile in this indication. 
• In November 2025, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved Caplyta (Lumateperone) as an adjunctive therapy to be used in combination with antidepressants for the treatment of major depressive disorder (MDD) in adults, marking an important expansion of its approved psychiatric indications.

Key Highlights:

• Major depressive disorder has a lifetime prevalence of 5–17 percent, with an average of 12 percent.
• The National Institute of Mental Health estimates that 8.3% of the US population (21.0 million people) have experienced a major depressive episode.
• The prevalence rate of this disorder is about double in women than in men.
• Though the average age of onset is around 40 years, new surveys reveal that the incidence is increasing in the younger population as a result of alcohol and other substance usage.
• Low income was revealed to be a significant risk factor for major depressive disorder in those under the age of 65.

Drugs:

Auvelity is a new N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity that is approved for the treatment of major depressive disorder in adults. Auvelity, developed by the US-based biopharmaceutical company Axsome Therapeutics, Inc, is an extended-release oral tablet containing 45mg dextromethorphan HBr and 105mg bupropion HCl.

SEP-363856 is a novel psychotropic agent that works through a unique mechanism involving agonism at Trace Amine-Associated Receptor 1 (TAAR1) and serotonin 5-HT1A receptors, without directly interacting with dopamine D2 or serotonin 5-HT2A receptors, which are commonly targeted by other antipsychotics. This dual action on TAAR1 and 5-HT1A receptors is believed to be integral to its efficacy in treating both positive and negative symptoms of schizophrenia.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the major depressive disorder market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the major depressive disorder market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current major depressive disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the major depressive disorder market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the major depressive disorder across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the major depressive disorder across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2020-2036) of major depressive disorder across the seven major markets?
• What is the number of prevalent cases (2020-2036) of major depressive disorder by age across the seven major markets?
• What is the number of prevalent cases (2020-2036) of major depressive disorder by gender across the seven major markets?
• What is the number of prevalent cases (2020-2036) of major depressive disorder by type across the seven major markets?
• How many patients are diagnosed (2020-2036) with major depressive disorder across the seven major markets?
• What is the size of the major depressive disorder patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend major depressive disorder of?
• What will be the growth rate of patients across the seven major markets?

Major Depressive Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for major depressive disorder drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the major depressive disorder market?
• What are the key regulatory events related to the major depressive disorder market?
• What is the structure of clinical trial landscape by status related to the major depressive disorder market?
• What is the structure of clinical trial landscape by phase related to the major depressive disorder market?
• What is the structure of clinical trial landscape by route of administration related to the major depressive disorder market?